Methods of treating cancer with HDAC inhibitors

Details for Australian Patent Application No. 2004283717 (hide)

International Classifications

Event Publications

8 June 2006 PCT application entered the National Phase

PCT publication WO2005/039498 Priority application(s): WO2005/039498

15 June 2006 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 17 May 2006

4 September 2008 Application Accepted

Published as AU-B-2004283717

4 December 2008 Amendment Made

The nature of the amendment is: Add co-inventor Kelly, William Kevin

18 December 2008 Alteration of Name

The name of the applicant has been altered to Aton Pharma, Inc.; Sloan-Kettering Institute for Cancer Research

18 December 2008 Assignment before Grant

Aton Pharma, Inc.; Sloan-Kettering Institute for Cancer Research The application has been assigned to Sloan-Kettering Institute for Cancer Research; Merck HDAC Research, LLC

8 January 2009 Standard Patent Sealed

21 May 2009 Offer to Surrender

Sloan-Kettering Institute for Cancer Research 1275 York Avenue , New York New York 10021; Merck HDAC Research, LLC 33 Avenue Louis Pasteur , MasBoston sachusetts 02115, the Patentee of Letters Patent 2004283717 dated 18.12.2008 for an invention titled ' Methods of treating cancer with HDAC inhibitors' offers to surrender the said Letters Patent. Any person desiring to be heard before the said offer to surrender is accepted must lodge a request to be heard within one month from the date of this journal.

9 July 2009 Innovation Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.